The researchers concluded that oART, with BH technique, shows promise in reducing PTV margins and OAR doses in gastric ...

Gastric cancer remains a formidable adversary, ranking as the fifth most common cancer and the third-leading cause of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

2020年1月20日，河北医科大学外科系在Oncotargets and Therapy（中科院四区 IF=2.7）刊上在线发表题为 "Silencing of LncRNA Metastasis-Associated Lung ...

New study and promising results from the first clinical trial in patients provide novel insights and new hope for one of ...

The clinical trial and a new study mark a significant leap in the fight against gastric cancer with peritoneal spread. Read ...

In tandem with this breakthrough, a clinical trial has demonstrated the potential of an innovative treatment strategy ...

The following is a summary of "Preoperative Chemoradiotherapy for Resectable Gastric Cancer," published in the September 2024 ...

Despite improvement in pathologic complete response with preoperative chemoradiation, the benefit did not extend to overall ...

I-Mab (IMAB) said that an expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody ...

Oberotatug ravtansine is under clinical development by Oxford BioTherapeutics and currently in Phase I for Gastric Cancer.

Annexuzlimab is under clinical development by MedAnnex and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate ...